Patents Examined by Zinna Northington Davis
  • Patent number: 10351528
    Abstract: A compound having a SF4 group on a pyridine ring is provided. Specifically, the compound is represented by the general formula (c): wherein k is 1 or 2; X is a hydrogen atom or a halogen atom; R1 is a hydrogen atom, a halogen atom, a substituted or unsubstituted alkyl group having 1 to 18 carbon atoms, a substituted or unsubstituted aryl group having 6 to 30 carbon atoms, or a nitro group; and R2 is a substituted or unsubstituted alkyl group having 1 to 18 carbon atoms or a substituted or unsubstituted aryl group having 6 to 30 carbon atoms.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 16, 2019
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Norio Shibata, Kohei Matsuzaki, Norimichi Saito
  • Patent number: 10351559
    Abstract: The invention relates to 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo [d] imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-5-yl) oxy)-3,4-dihydro-1, 8-naphthyridin-2 (1H)-one (Compound 1) maleate salts, in particular the sesqui-maleate salt and its crystalline forms, methods of preparation, pharmaceutical compositions, and therapeutic uses for treatment of diseases or disorders mediated by BRAF or other kinases.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: July 16, 2019
    Assignee: BEIGENE, LTD.
    Inventors: Guoliang Zhang, Changyou Zhou
  • Patent number: 10344017
    Abstract: The invention provides compounds of formula (I) or a tautomer, stereoisomer, N-oxide, pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the prophylaxis or treatment of a disease state or condition mediated by ERK5, in particular cancers.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 9, 2019
    Inventors: Tristan Reuillon, Duncan Miller, Stephanie Myers, Lauren Molyneux, Celine Cano, Ian Hardcastle, Roger Griffin, Laurent Rigoreau, Bernard Golding, Martin Noble
  • Patent number: 10329302
    Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: June 25, 2019
    Assignee: Pfizer Inc.
    Inventors: John David Trzupek, Katherine Lin Lee, Mark Edward Bunnage, Seungil Han, David Hepworth, Frank Eldridge Lovering, John Paul Mathias, Nikolaos Papaioannou, Betsy Susan Pierce, Joseph Walter Strohbach, Stephen Wayne Wright, Christoph Wolfgang Zapf, Lori Krim Gavrin, Arthur Lee, David Randolph Anderson, Kevin Joseph Curran, Christoph Martin Dehnhardt, Eddine Saiah, Joel Adam Goldberg, Xiaolun Wang, Horng-Chih Huang, Richard Vargas, Michael Dennis Lowe, Akshay Patny
  • Patent number: 10322111
    Abstract: The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: June 18, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Gary J. Bridger, Renato T. Skerlj, Al Kaller, Curtis Harwig, David Earl Bogucki, Trevor R. Wilson, Jason B. Crawford, Ernest J. McEachern, Bem Atsma, Siqiao Nan, Yuanxi Zhou, Dominique Schols, Christopher Dennis Smith, Maria Rosario DiFluri
  • Patent number: 10323036
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: June 18, 2019
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Jeremy Robert Greenwood, Geraldine C. Harriman, Silvana Marcel Leit de Moradei, Craig E. Masse, Thomas H. McLean, Sayan Mondal
  • Patent number: 10315994
    Abstract: The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing cyclic compounds capable of absorbing electromagnetic radiation energy and having improved photostability due to the presence and location of one or more fluorine groups in relation to the double bond of the ring.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: June 11, 2019
    Assignee: Commomwealth Scientific and Industrial Research Organization
    Inventors: John Ryan, Mark York
  • Patent number: 10316056
    Abstract: Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity. Also, a method of improving muscle quality in obese mammals and treating and/or preventing of obesity and associated complications and/or pathologies, advantageously type 2 diabetes and metabolic syndrome, using the chemical compounds.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: June 11, 2019
    Assignees: BIOPHYTIS, SORBONNE UNVERSITÉ
    Inventors: René Lafont, Waly Dioh, Sophie Raynal, Stanislas Veillet, Franck Lepifre, Jean-Denis Durand
  • Patent number: 10314832
    Abstract: The present application discloses a compound which is which activates Wnt/?-catenin signaling and thus treats or prevents diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: June 11, 2019
    Assignee: Samumed, LLC
    Inventors: Sunil Kumar Kc, David Mark Wallace, John Hood, Charlene F. Barroga
  • Patent number: 10308638
    Abstract: In alternative embodiments, provided are selective agonists having a high affinity for the alpha7 nicotinic acetylcholine receptor (?7 nAChR), assays for selectivity of nicotinic receptor subtype and ligand-gated ion channel subtype based on receptor occupation and response, behavioral assessments for reversing cognitive impairment after scopolamine treatment, enhancing memory retention over time, pharmaceutical compositions and formulations and devices comprising them, and methods for making and using them, including characterizing and efficiently assaying them for receptor subtype selectivity. In alternative embodiments, provided are substituted anti 1,2,3-triazoles compounds with high affinity, and selective binding, for the alpha7 nicotine acetylcholine receptor (?7 nAChR), as exemplified by 5-(1-(2-(Piperidin-1-yl)ethyl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND1”), 5-((quinuclid-3-yl)-1H-1,2,3-triazol-4-yl)-1H-indole (“IND8”) and 3-(4-hydroxyphenyl-1,2,3-triazol-1-yl) quinuclidine (“QND8”).
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 4, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Palmer Taylor, Gisela-Andrea Camacho-Hernandez, Karl Barry Sharpless, M. G. Finn, Valery Fokin
  • Patent number: 10308607
    Abstract: The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 4, 2019
    Assignee: HORIZON ORPHAN LLC
    Inventors: Todd C. Zankel, Sara Louise Isbell, Amanda Anne Ko
  • Patent number: 10301327
    Abstract: A method for preparing an anionic polymerization initiator, a device for manufacturing the same, and an anionic polymerization initiator prepared therefrom is provided. And the method for preparing an anionic polymerization initiator according to the present invention is characterized in that in a continuous reactor an amine compound of Formula 1 and/or Formula 2; an organometallic compound; and/or a conjugated diene compound are introduced in the form of a solution and reacted.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: May 28, 2019
    Assignee: LG Chem, Ltd.
    Inventors: Jae Hoon Choe, Dong Cheol Choe, Hyun Ju Kim, Hyeon Hui Kim, Jong Young Choi, Jung Yong Lee, Woong Chan Jeong, Jong Min Shin, Chan Joong Kim, Kwang Ho Song
  • Patent number: 10299477
    Abstract: A compound represented by Formula (1) or a salt thereof is provided. R1 represents a C1-C6 alkyl group optionally substituted, a C1-C6 haloalkyl group or the like, R2 represents a halogen atom, a C1-C6 alkyl group optionally substituted, a C1-C6 alkyloxy group optionally substituted or the like, R3 represents a hydrogen atom, a halgenatom, C1-C6 alkyl group optionally substituted or the like, n represents an integer of 0 to 5, X represents an oxygen atom or a sulfur atom, Y represents a phenyl group or a pyridyl group that is substituted with substituent at an ortho position, and the bond with a broken line indicates a double bond or a single bond.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: May 28, 2019
    Assignee: MITSUI CHEMICALS AGRO, INC.
    Inventors: Hideki Umetani, Hideaki Ikishima, Ryohei Naito, Toshiyuki Kouno, Takeshi Fukumoto, Satoshi Yutani, Toshiaki Ohara, Akihiro Nishida
  • Patent number: 10294247
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: May 21, 2019
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Patent number: 10280143
    Abstract: There is provided a process for preparing a compound represented by the following general formula (1) or a salt thereof, which comprises exchanging one or more of an amino proton in a compound represented by the following general formula (2) or a salt thereof to deuterium, and after the exchanging, converting a deuterium-exchanged compound of the compound represented by the general formula (2) or a salt thereof into the compound represented by the general formula (1) or a salt thereof: wherein, in the general formula (1), one, or two or more of hydrogen atom may be substituted with their isotope; and in the general formula (2), each of R1 is independently hydrogen atom, tert-butyloxycarbonyl group or benzyloxycarbonyl group, and R2 is independently tert-butyl group, benzyl group, methyl group or ethyl group.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: May 7, 2019
    Assignee: SOPHIA SCHOOL CORPORATION
    Inventor: Toyonobu Usuki
  • Patent number: 10278967
    Abstract: The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: May 7, 2019
    Assignee: Rhodes Technologies
    Inventors: C. Frederick M. Huntley, Erik Wayne Kataisto, Helge Alfred Reisch, Archana Sharma
  • Patent number: 10272081
    Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: April 30, 2019
    Assignee: Aquinox Pharmaceuticals (Canada) Inc.
    Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
  • Patent number: 10273212
    Abstract: The present invention is related to a two-step carboxylation reaction of an aryl group using continuous flow reaction conditions. This process permits large scale synthesis of useful reaction products in high yield.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: April 30, 2019
    Assignee: SARCODE BIOSCIENCE INC.
    Inventors: Scott Tweedie, Sripathy Venkatraman, James Zeller
  • Patent number: 10272078
    Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: April 30, 2019
    Assignee: FibroGen, Inc.
    Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
  • Patent number: 10265323
    Abstract: Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: April 23, 2019
    Assignees: LES LABORATOIRES SERVIER, VERNALS (R&D) LTD
    Inventors: Arnaud Le Tiran, Thierry Le Diguarher, Jérôme-Benoît Starck, Jean-Michel Henlin, Anne-Françoise Guillouzic, Guillaume De Nanteuil, Olivier Geneste, Imre Fejes, János Tatai, Miklós Nyerges, James Edward Paul Davidson, James Brooke Murray, I-Jen Chen, Didier Durand